Sequentia, a CataloniaBio & HealthTech member, has received an EIC grant from the European Commission, part of the EIC Accelerator program, that supports SMEs to scale up high impact innovations with the potential to create new markets or disrupt existing ones. In addition to financial support, all projects benefit from a range of Business Acceleration Services that provide access to leading expertise, corporates, investors and ecosystem actors.

Sequentia was one of the 99 companies that were selected to benefit from the programme and will be able to take MICK to the next level. MICK is the first translational microbiome platform for healthcare practice. MICK translates the taxonomical and functional microbiome characterisation data into actionable information allowing healthcare professionals to use it in the clinical decision-making process.

With the award of this grant and during the next two years Sequentia will be able to step forward their technology, perform further clinical validations, and advance market readiness with the aim to become the ultimate microbiome software solution for healthcare in Europe.